Thursday, 8 March 2018

Large-molecule Injectable Drugs Market: Prevalence of Chronic Diseases to Drive the Growth

One of the aspects of finding the accurate method for new treatments is selecting a precise technology platform. Molecules used as active substances can be classified into two types: large molecules and small molecules. These two types vary not only in terms of size, but also in terms of method of manufacture, mechanism of action in the body, and their preciseness for assured drug forms.


Large molecules (biologics), also called as biopharmaceuticals, is a class of drugs that are based on proteins which have a therapeutic effect. Some of the key therapeutic proteins which are widely used as biologic drugs are victoza, rebif, levemir, humalog, Lantus, enbrel, novolog, and epogen. Biologics consist of more than 1300 amino acids. These can be as heavy as 150kDa. These are advanced versions of endogenous human proteins. These large molecules bind to a specific cell receptors that are associated with the disease process. Usually healthy immune cells are not attacked in this process. Hence, large molecules have fewer side-effects compared to classic chemotherapy. These are extensively used in cancer therapies, cardiac therapies, and diabetes treatment.

Usually, large molecules are administered into the patient’s body via infusion or injection. If they are taken orally, like other proteins and amino acids in the body, they would be easily digested in the intestines and the stomach and would become ineffective. Biologicals are manufactured by employing a biotechnological process; for example, using genetically modified cells of microbes such as mammalian cell lines, yeasts, and bacteria.


The global large-molecule injectable drugs market is projected to expand rapidly in the next few years. Some of the driving factors for the market are increase in the prevalence of chronic diseases such as cancer and diabetes, rise in the number of drug manufacturers that focus on the development of biopharmaceuticals to treat different types of cancer, and increase in investments in R&D activities. On the other hand, high treatment costs, discontinuation of some of the injectable drugs for cancer treatment, and strict regulations imposed by some of the regulatory bodies are likely to restrain the global large-molecule injectable drugs market during the forecast period.

The global large-molecule injectable drugs market has been segmented based on application, distribution channel, and geographical region. Based on application, the market has been divided into oncology, cardiovascular diseases, vaccines, and others. Based on distribution channel, the market has been divided into hospital pharmacies, retail pharmacies, and e-commerce.

Based on region, the global large-molecule injectable drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is projected to expand at a rapid pace in the near future, owing to well-developed health care systems, proper reimbursement scenario, and adoption of newly advanced techniques in the region. North America is anticipated to be followed by Europe and Asia Pacific. Presence of key players, increase in investments in R&D activities by top market players, alliance of key market players with research institutes are some of the factors driving the global large-molecule injectable drugs market.


Key players operating in the global large-molecule injectable drugs market are Medtronic Plc, AstraZeneca plc, GlaxoSmithKline Plc., Biogen Idec, Novartis AG, Baxter International Inc., Amgen Inc., Sun Pharmaceutical Industries Limited, Johnson & Johnson, Roche Ag, and Pfizer.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

No comments:

Post a Comment